Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

BACKGROUND: Often, patients with primary immunodeficiency diseases (PID), which are marked by the absence or loss of functional antibodies, require lifelong treatment with immunoglobulin (IG) replacement therapy administered either intravenously (intravenous immunoglobulin [IVIG]) or subcutaneously...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Immunol
Autors principals: Meckley, Lisa M., Wu, Yanyu, Ito, Diane, Berner, Todd, McCoy, Barbara, Yel, Leman
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7197164/
https://ncbi.nlm.nih.gov/pubmed/32366233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12865-020-00346-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars